Investor Presentation H1 2023

34 Investor presentation First six months of 2023 Novo NordiskⓇ Pipeline supports significant growth opportunities across all four strategic focus areas PHASE 1 NN1845 - GSI NN1471 - Pumpinsulin NN9041 - DNA Immunotherapy NN9541 OW GLP-1/GIP co-agonist NN9904 Once weekly oral sema NN9487 Oral Amycretin NN6020 DCR-AUD¹ NN6582 - LXR(a) in NASH NN6581 - MARC1 in NASH NN9003 - Stem Cells in HF NN9001 - Stem Cells in PD PHASE 2 NN9388 Cagrisema NN7533 Ndec in SCD PHASE 3 NN1535 Icosema - - NN9924 Oral Semaglutide 25 and 50 mg NN7535 Etavopivat in Beta thalassemia NN9536 - Semaglutide 7.2 mg NN9931 - Gilead in NASH NN9838 Cagrisema NN9500 FGF-21 in NASH - NN6021 - Belcesiran in AATLD NN6019-ATTR Cardiomyopathy - NN9932 - Oral Semaglutide 50 mg obesity² NN9931 Semaglutide 2.4 mg in NASH NN6535 Semaglutide 14.0 mg in AD NN6018 Ziltivekimab in ASCVD NN6018 - Ziltivekimab in HFPEF NN7769 Mim8 in HA - Etavopivat in SCD SUBMITTED NN1436- - Insulin Icodec NN7415 Concizumab³ in HWI NN7022 Nedosiran in PH APPROVED TresibaⓇ XultophyⓇ LevemirⓇ RyzodegⓇ NovoMixⓇ FiaspⓇ NovoRapidⓇ RybelsusⓇ OzempicⓇ4 VictozaⓇ Diabetes care Obesity care NN7535 Other PHASE 3 trials SOUL - Oral semaglutide 14.0 mg CVOT FOCUS Semaglutide 1.0 mg in diabetic retinopathy FLOW-Semaglutide 1.0 mg in CKD STRIDE Semaglutide 1.0 mg in PAD STEP Semaglutide 2.4 mg in HFPEF SELECT Semaglutide 2.4 mg in obese population Rare blood disorders Rare endocrine disorders Other serious chronic diseases WegovyⓇ SaxendaⓇ NovoSevenⓇ NovoEight® EsperoctⓇ NovoThirteenⓇ Refixia® AlhemoⓇ5 NorditropinⓇ Sogroya® 1 Dicerna-Alcohol Use Disorder; 225 mg trial also initiated; 3 Submitted to EU/JP for HwI,; 4 Higher doses of injectable semaglutide (8 mg and 16 mg) tested in phase 2; 5 Approved in Canada for HBWI; AATLD: Alpha-1 Antitrypsin Deficiency-associated Liver Disease; AD: Alzheimer's Disease; ASCVD: Atherosclerotic Cardiovascular Disease; ATTR: Transthyretin amyloidosis; CKD: chronic kidney disease; CVOT: Cardiovascular outcome trial; FGF-21: Fibroblast growth factor 21; GHD: Growth hormone disorder; GSI: Glucose Sensitive Insulin; HA: Haemophilia A; HF: Heart failure; HFPEF: heart failure with preserved ejection fraction; HwI: Haemophilia with inhibitors; JP: Japan; LXR(a): Liver X receptor alpha; MARC1: Mitochondrial amidoxime reducing component 1; MDS: myelodysplastic syndrome; NASH: Nonalcoholic Steatohepatitis; PAD: Peripheral arterial disease; PD: Parkinson's Disease; PH: Primary hyperoxaluria; SCD: Sickle cell disease; Sema: Semaglutide; US: United States.

View entire presentation